JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarau, H. M.
Right arrow Articles by Hay, D. W. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarau, H. M.
Right arrow Articles by Hay, D. W. P.

Vol. 281, Issue 3, 1303-1311, 1997

Nonpeptide Tachykinin Receptor Antagonists: I. Pharmacological and Pharmacokinetic Characterization of SB 223412, a Novel, Potent and Selective Neurokinin-3 Receptor Antagonist

Henry M. Sarau, Don E. Griswold, William Potts, James J. Foley, Dulcie B. Schmidt, Edward F. Webb, Lenox D. Martin, Mary E. Brawner, Nabil A. Elshourbagy, Andrew D. Medhurst, Giuseppe A. M. Giardina and Douglas W. P. Hay

Departments of Pulmonary Pharmacology (H.M.S., J.J.F., D.B.S., D.W.P.H.), Immunopharmacology (D.E.G., E.F.W., L.D.M.), Drug Metabolism and Pharmacokinetics (W.P.), Gene Expression Sciences (M.E.B.) and Molecular Genetics (N.A.E.), SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, 19406, Department of Neurology Research (A.D.M.), SmithKline Beecham Pharmaceuticals, Harlow, Essex, CM19 5AW, UK, and Department of Chemistry (G.A.M.G.), SmithKline Beecham Pharmaceuticals, 20021 Baranzate, Milan, Italy

The in vitro and in vivo pharmacological profile of SB 223412 [(S)-(-)-N-(alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide], a novel human NK-3 (hNK-3) receptor antagonist, is described. SB 223412 demonstrated enantioselective affinity for inhibition of [125I][MePhe7]neurokinin B (NKB) binding to membranes of CHO cells expressing the hNK-3 receptor (CHO hNK-3). SB 223412, the (S)-isomer, (Ki = 1.0 nM), has similar affinity as the natural ligand, NKB (Ki = 0.8 nM) and another nonpeptide NK-3 receptor antagonist, SR 142801 (Ki = 1.2 nM). SB 223412 was selective for hNK-3 receptors compared with hNK-1 (>10,000-fold selective) and hNK-2 receptors (>140-fold selective), and selectivity was further demonstrated by its lack of effect, in concentrations up to 1 or 10 µM, in >60 receptor, enzyme and ion channel assays. SB 223412 enantioselectively inhibited the NKB-induced Ca++ mobilization in HEK 293 cells stably expressing the hNK-3 receptor. SB 223412 (10-1,000 nM) produced concentration-dependent rightward shifts in NKB-induced Ca++ mobilization concentration-response curves with a Kb value of 3 nM. In addition, SB 223412 antagonized senktide-induced contraction in the isolated rabbit iris sphincter muscle (Kb = 1.6 nM). In mice, oral administration of SB 223412 produced dose-dependent inhibition of behavioral responses induced by the NK-3 receptor-selective agonist, senktide (ED50 = 12.2 mg/kg). Pharmacokinetic evaluation of SB 223412 in rat and dog indicated low plasma clearance, oral bioavailability and high and sustained plasma concentrations after 4 to 8 mg/kg oral dosages. The preclinical profile of SB 223412 (high affinity, selectivity, reversibility and oral activity) suggests that it will be a useful tool compound to define the physiological and pathophysiological roles of NK-3 receptors.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
P. Malherbe, C. Bissantz, A. Marcuz, C. Kratzeisen, M.-T. Zenner, J. G. Wettstein, H. Ratni, C. Riemer, and W. Spooren
Me-Talnetant and Osanetant Interact within Overlapping but Not Identical Binding Pockets in the Human Tachykinin Neurokinin 3 Receptor Transmembrane Domains
Mol. Pharmacol., June 1, 2008; 73(6): 1736 - 1750.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Tian, D. Wilkins, and C. W. Scott
Neurokinin-3 Receptor-Specific Antagonists Talnetant and Osanetant Show Distinct Mode of Action in Cellular Ca2+ Mobilization but Display Similar Binding Kinetics and Identical Mechanism of Binding in Ligand Cross-Competition
Mol. Pharmacol., March 1, 2007; 71(3): 902 - 911.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. C. Myers, R. G. Goldie, and D. W. P. Hay
A Novel Role for Tachykinin Neurokinin-3 Receptors in Regulation of Human Bronchial Ganglia Neurons
Am. J. Respir. Crit. Care Med., February 1, 2005; 171(3): 212 - 216.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. L. Podolin, B. J. Bolognese, J. J. Foley, D. B. Schmidt, P. T. Buckley, K. L. Widdowson, Q. Jin, J. R. White, J. M. Lee, R. B. Goodman, et al.
A Potent and Selective Nonpeptide Antagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit
J. Immunol., December 1, 2002; 169(11): 6435 - 6444.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. J. Canning, S. M. Reynolds, L. U. Anukwu, R. Kajekar, and A. C. Myers
Endogenous neurokinins facilitate synaptic transmission in guinea pig airway parasympathetic ganglia
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R320 - R330.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. W. P. Hay, G. A. M. Giardina, D. E. Griswold, D. C. Underwood, C. J. Kotzer, B. Bush, W. Potts, P. Sandhu, D. Lundberg, J. J. Foley, et al.
Nonpeptide Tachykinin Receptor Antagonists. III. SB 235375, a Low Central Nervous System-Penetrant, Potent and Selective Neurokinin-3 Receptor Antagonist, Inhibits Citric Acid-Induced Cough and Airways Hyper-reactivity in Guinea Pigs
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 314 - 323.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Langlois, P. te Riele, C. Wintmolders, J. E. Leysen, and M. Jurzak
Use of the beta -Imager for Rapid ex Vivo Autoradiography Exemplified with Central Nervous System Penetrating Neurokinin 3 Antagonists
J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 712 - 717.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. M. Sarau, D. E. Griswold, B. Bush, W. Potts, P. Sandhu, D. Lundberg, J. J. Foley, D. B. Schmidt, E. F. Webb, L. D. Martin, et al.
Nonpeptide Tachykinin Receptor Antagonists. II. Pharmacological and Pharmacokinetic Profile of SB-222200, a Central Nervous System Penetrant, Potent and Selective NK-3 Receptor Antagonist
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 373 - 381.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
H. M. Sarau, J. L. Mooney, D. B. Schmidt, J. J. Foley, P. T. Buckley, G. A. M. Giardina, D. Y. Wang, J. A. Lee, and D. W. P. Hay
Evidence That the Proposed Novel Human "Neurokinin-4" Receptor Is Pharmacologically Similar to the Human Neurokinin-3 Receptor but Is Not of Human Origin
Mol. Pharmacol., September 1, 2000; 58(3): 552 - 559.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.